Gene Study for Prostate Cancer

Precision-Based Genomics in Prostate Cancer

Recruiting Observational Study
Prostate Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 120
Sex
Male
Study type
Observational
Participants needed
2,000 (estimated)
Sponsor
National Cancer Institute (NCI) · NIH
Who this trial is looking for

This trial is looking for adult men with prostate cancer who have specific gene mutations or a strong positive response to treatment. Participants will provide health information over the phone and may give blood or urine samples for gene research.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am a man aged 18 or older
  • I have been diagnosed with prostate cancer
  • I have specific gene mutations related to my cancer
  • I have had a strong positive response to treatment

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how aggressive the disease is. Objective: To look at gene mutations in men with prostate cancer as well as the course of their disease to better understand h…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
* INCLUSION CRITERIA: * Subjects with histologically confirmed prostate cancer. * Must have known germline and/or somatic variants in PIK3 and/or AKT, PALB2, BRIP1, RAD50, RAD51, RAD54, RB1, SPOP, Wnt/B-catenin pathway, CDK12, and/or MMR genes: MLH1, MSH2, MSH6, PMS2, and EPCAM and/or TMB-high(\[def…
Contacts

Katherine O Lee-Wisdom, R.N.

(240) 858-3525

katherine.lee-wisdom@nih.gov

CONTACT

Fatima H Karzai, M.D.

(301) 480-7174

fatima.karzai@nih.gov

CONTACT